These two investments look very appealing to me. The post Looking for ASX growth shares? I rate these 2 as buys appeared ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as ...

Raymond James initiated coverage of Samsara (IOT) with a Market Perform rating. The shares currently reflect a clear-cut leadership position, a ...

The Philippine Atmospheric, Geophysical and Astronomical Services Administration (PAGASA) on Wednesday announced it is ...

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Q2 2025 Results Conference Call February 24, 2025 7:00 PM ETCompany ParticipantsJustin Nuich - Chief Executive ...

A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for ...

People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...

Dr. Todd Ellerin says the compounded pharmacy drugs are regulated on the state level, but most do not possess FDA regulation like brand name drugs ...

Core & Main, Inc. (CNM) has strong growth prospects due to aging infrastructure, reshoring trends, and a recovering ...